clinical trial · NCT04752696
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Cardiff Oncology·phase2·terminated·n = 41
Pancreatic Ductal AdenocarcinomaOnvansertibNanoliposomal irinotecanLeucovorinFluorouracil
brief summary
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic PDAC.
started
May 25, 2021
primary completion
Dec 24, 2024
completion
Dec 24, 2024
last updated
Nov 4, 2026
official title
A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol